Literature DB >> 18591336

Statistical analysis of exacerbation rates in COPD: TRISTAN and ISOLDE revisited.

O N Keene1, P M A Calverley, P W Jones, J Vestbo, J A Anderson.   

Abstract

Various statistical methods have been used to measure the impact of treatment on chronic obstructive pulmonary disease (COPD) exacerbations. Poisson regression has recently been recommended as the appropriate method but the model does not satisfactorily account for variability between patients. In contrast, use of a negative binomial model, which corresponds to assuming a separate Poisson parameter for each patient, offers a more appealing approach. The present paper reviews analysis methods, with particular focus on the negative binomial model. To illustrate the differences that arise from using different analysis methods, we have reanalysed data from two large studies which, among other objectives, investigated the effectiveness of inhaled corticosteroids in reducing COPD exacerbation rates. Using the negative binomial model to reanalyse data from the TRISTAN and ISOLDE studies, the overall estimates of exacerbation rates on each treatment arm are higher and the confidence intervals for comparisons between treatments are wider, but the overall conclusions of TRISTAN and ISOLDE regarding reduction of exacerbations remain unchanged. The negative binomial approach appears to provide a better fit to the distribution of the data than earlier methods and is currently the method of choice. Research needs to continue on further methods to improve the analysis of exacerbation data.

Entities:  

Mesh:

Year:  2008        PMID: 18591336     DOI: 10.1183/09031936.00161507

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  28 in total

Review 1.  Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease.

Authors:  Sally Spencer; Charlotta Karner; Christopher J Cates; David J Evans
Journal:  Cochrane Database Syst Rev       Date:  2011-12-07

2.  Vitamin D levels and risk of acute exacerbations of chronic obstructive pulmonary disease: a prospective cohort study.

Authors:  Ken M Kunisaki; Dennis E Niewoehner; John E Connett
Journal:  Am J Respir Crit Care Med       Date:  2011-11-10       Impact factor: 21.405

3.  Impaired Sleep Quality in COPD Is Associated With Exacerbations: The CanCOLD Cohort Study.

Authors:  Matthew Shorofsky; Jean Bourbeau; John Kimoff; Rachel Jen; Atul Malhotra; Najib Ayas; Wan C Tan; Shawn D Aaron; Don D Sin; Jeremy Road; Kenneth R Chapman; Denis E O'Donnell; François Maltais; Paul Hernandez; Brandie L Walker; Darcy Marciniuk; Marta Kaminska
Journal:  Chest       Date:  2019-05-28       Impact factor: 9.410

Review 4.  Combination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease.

Authors:  Charlotta Karner; Christopher J Cates
Journal:  Cochrane Database Syst Rev       Date:  2011-03-16

Review 5.  Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.

Authors:  Donald P Tashkin; Leonardo M Fabbri
Journal:  Respir Res       Date:  2010-10-29

6.  Mepolizumab and exacerbations of refractory eosinophilic asthma.

Authors:  Pranabashis Haldar; Christopher E Brightling; Beverley Hargadon; Sumit Gupta; William Monteiro; Ana Sousa; Richard P Marshall; Peter Bradding; Ruth H Green; Andrew J Wardlaw; Ian D Pavord
Journal:  N Engl J Med       Date:  2009-03-05       Impact factor: 91.245

7.  A New Bronchodilator Response Grading Strategy Identifies Distinct Patient Populations.

Authors:  James E Hansen; Asli G Dilektasli; Janos Porszasz; William W Stringer; Youngju Pak; Harry B Rossiter; Richard Casaburi
Journal:  Ann Am Thorac Soc       Date:  2019-12

8.  Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol.

Authors:  Peter M A Calverley; Fernando J Martinez; Leonardo M Fabbri; Udo-Michael Goehring; Klaus F Rabe
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-06-20

9.  Locomotor development prediction based on statistical model parameters identification.

Authors:  A V Wildemann; A A Tashkinov; V A Bronnikov
Journal:  Comput Math Methods Med       Date:  2012-12-10       Impact factor: 2.238

10.  A lifetime Markov model for the economic evaluation of chronic obstructive pulmonary disease.

Authors:  Petra Menn; Reiner Leidl; Rolf Holle
Journal:  Pharmacoeconomics       Date:  2012-09-01       Impact factor: 4.558

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.